PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED REFRACTORY

This adverse event was reported 13 times

PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ROMIDEPSIN 3 0.0018
1 BRENTUXIMAB VEDOTIN 2 0.0002
2 VINORELBINE 1 0.0001
3 BENDAMUSTINE HCL 1 0.0001
4 DOXORUBICIN HYDROCHLORIDE 1 0.0000
5 PREDNISOLONE ORAL SOLUTION 4 0.0000
6 GEMCITABINE HYDROCHLORIDE 1 0.0000
7 CYCLOPHOSPHAMIDE FOR INJECTION 3 0.0000
8 CYCLOPHOSPHAMIDE 3 0.0000
9 ANTI-ITCH CREAM 1 0.0000
See all drugs enriched for association with PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED REFRACTORY

PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Histone Deacetylase Inhibitor [EPC] 1 0.0003
1 CD30-directed Immunoconjugate [EPC] 2 0.0002
2 Alkylating Drug [EPC] 3 0.0000
3 Corticosteroid [EPC] 6 0.0000
4 Thalidomide Analog [EPC] 2 0.0000
5 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
6 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED REFRACTORY